US FDA Panel Split on Sotagliflozin for Type 1 Diabetes US FDA Panel Split on Sotagliflozin for Type 1 Diabetes

The 8-8 tie reflected the FDA advisory panel ' s struggle in assessing the drug ' s glycemic and other benefits against an elevated risk for diabetic ketoacidosis.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news